Free Access to FDA 483s
Recommendation

27/28 May 2026
Batch Manufacturing Documents: from Preparation to Operational Excellence
Many people in the pharmaceutical industry are aware of the fact that Warning Letters issued by the US Food and Drug Administration (FDA) are published on the FDA website.
But the Office of Regulatory Affaires (ORA) is also publishing other copies of ORA domestic inspection and related records. This is done either proactively at ORA's discretion or because they are "frequently requested" per the Electronic Freedom of Information Act Amendments of 1996.
Here is an overview on what is available:
- 483 observations are best to be seen at the "frequently requested or proactively posted compliance records" site
- Enforcement Reports, Recalls, Import Alerts, Import Refusals etc. can be found at the data sets page
- Warning Letters are accessible on a dedicated page for Warning Letters
- Establishment Inspection Reports can be searched in the ORA FOIA Electronic Reading Room
- Persons currently debarred pursuant to sections 306(a) or (b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 335(a) or (b) are listed in the FDA Debarment list
- Other ORA documents cab be found on the ORA home page.
Related GMP News
28.04.2026FDA remains active in Europe - further Inspections despite MRAs
22.04.2026No Validation, No Controls, and No Suitable Rooms and Equipment - Extensive Warning Letter
25.03.2026FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue
18.03.2026FDA Issues Draft Guidance on Responding to Form 483 Observations
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight


